Last reviewed · How we verify
vilanterol (VI)
vilanterol (VI) is a Long-acting beta-2 agonist (LABA) Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for Chronic obstructive pulmonary disease (COPD) maintenance therapy, Asthma maintenance therapy (in combination with inhaled corticosteroids).
Vilanterol is a long-acting beta-2 adrenergic agonist (LABA) that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
Vilanterol is a small molecule used in combination with other medications for the treatment of asthma and chronic obstructive pulmonary disease. It is part of fixed-dose combinations such as FF/UMEC/VI, which includes fluticasone furoate and umeclidinium bromide.
At a glance
| Generic name | vilanterol (VI) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting beta-2 agonist (LABA) |
| Target | Beta-2 adrenergic receptor (ADRB2) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Vilanterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP and leads to smooth muscle relaxation and airway dilation. This effect is sustained over 24 hours due to its long half-life and depot formulation, making it suitable for once-daily maintenance therapy in obstructive airway diseases.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Asthma maintenance therapy (in combination with inhaled corticosteroids)
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Tachycardia
Key clinical trials
- Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma (PHASE4)
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD (PHASE4)
- A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma (PHASE3)
- 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation (PHASE4)
- Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma (PHASE3)
- Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma (PHASE3)
- Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- vilanterol (VI) CI brief — competitive landscape report
- vilanterol (VI) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about vilanterol (VI)
What is vilanterol (VI)?
How does vilanterol (VI) work?
What is vilanterol (VI) used for?
Who makes vilanterol (VI)?
What drug class is vilanterol (VI) in?
What development phase is vilanterol (VI) in?
What are the side effects of vilanterol (VI)?
What does vilanterol (VI) target?
Related
- Drug class: All Long-acting beta-2 agonist (LABA) drugs
- Target: All drugs targeting Beta-2 adrenergic receptor (ADRB2)
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Indication: Drugs for Asthma maintenance therapy (in combination with inhaled corticosteroids)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing